Breaking News
7 minutes ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Idorsia's Phase 3 PRECISION data show aprocitentan cuts albuminuria significantly through Week 36, strengthening the renal evidence base for potential label expansion.
Pharma Now Editorial Team

Roche advances enicepatide and petrelintide to Phase III and launches a combination trial, signalling significant CMC and manufacturing scale-up ahead.
Pharma Now Editorial Team

Idorsia's Phase 1 high-dose cohort confirms dose-dependent IgG immunogenicity for its synthetic glycan C. difficile vaccine, with partnership and scale-up next.
Pharma Now Editorial Team

Novartis presents 31 EULAR 2026 abstracts spanning secukinumab, ianalumab, and CAR-T rap-cel across multiple autoimmune indications.
Pharma Now Editorial Team
